289 related articles for article (PubMed ID: 18215600)
1. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.
McLean DS; Ravid S; Blazing M; Gersh B; Shui A; Cannon CP
Am Heart J; 2008 Feb; 155(2):298-302. PubMed ID: 18215600
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Brilakis ES; de Lemos JA; Cannon CP; Wiviott SD; Murphy SA; Morrow DA; Sabatine MS; Banerjee S; Blazing MA; Califf RM; Braunwald E
Am J Cardiol; 2008 Sep; 102(5):552-8. PubMed ID: 18721511
[TBL] [Abstract][Full Text] [Related]
3. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
[TBL] [Abstract][Full Text] [Related]
4. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
[TBL] [Abstract][Full Text] [Related]
5. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
[TBL] [Abstract][Full Text] [Related]
6. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; Cairns R; Morrow DA; Rifai N; Kirtane AJ; McCabe CH; Skene AM; Gibson CM; Ridker PM; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1417-24. PubMed ID: 16226164
[TBL] [Abstract][Full Text] [Related]
7. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
Austin PC; Mamdani MM
Circulation; 2005 Aug; 112(9):1296-300. PubMed ID: 16116054
[TBL] [Abstract][Full Text] [Related]
8. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Rouleau J
Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
[TBL] [Abstract][Full Text] [Related]
9. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
Ray KK; Cannon CP; McCabe CH; Cairns R; Tonkin AM; Sacks FM; Jackson G; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1405-10. PubMed ID: 16226162
[TBL] [Abstract][Full Text] [Related]
10. Dose-related effect of statins on atrial fibrillation after cardiac surgery.
Kourliouros A; De Souza A; Roberts N; Marciniak A; Tsiouris A; Valencia O; Camm J; Jahangiri M
Ann Thorac Surg; 2008 May; 85(5):1515-20. PubMed ID: 18442529
[TBL] [Abstract][Full Text] [Related]
11. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial.
Reid IR; Tonkin A; Cannon CP
Bone; 2005 Aug; 37(2):190-1. PubMed ID: 15936996
[TBL] [Abstract][Full Text] [Related]
13. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Ray KK; Cannon CP
Am J Cardiol; 2005 Sep; 96(5A):54F-60F. PubMed ID: 16126024
[TBL] [Abstract][Full Text] [Related]
14. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Wiviott SD; de Lemos JA; Cannon CP; Blazing M; Murphy SA; McCabe CH; Califf R; Braunwald E
Circulation; 2006 Mar; 113(11):1406-14. PubMed ID: 16534008
[TBL] [Abstract][Full Text] [Related]
15. Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study).
Tung P; Wiviott SD; Cannon CP; Murphy SA; McCabe CH; Gibson CM
Am J Cardiol; 2009 Apr; 103(8):1056-60. PubMed ID: 19361589
[TBL] [Abstract][Full Text] [Related]
16. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
Wiviott SD; Cannon CP; Morrow DA; Ray KK; Pfeffer MA; Braunwald E;
J Am Coll Cardiol; 2005 Oct; 46(8):1411-6. PubMed ID: 16226163
[TBL] [Abstract][Full Text] [Related]
17. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
[TBL] [Abstract][Full Text] [Related]
18. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery.
Song YB; On YK; Kim JH; Shin DH; Kim JS; Sung J; Lee SH; Kim WS; Lee YT
Am Heart J; 2008 Aug; 156(2):373.e9-16. PubMed ID: 18657672
[TBL] [Abstract][Full Text] [Related]
19. Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
Bang CN; Gislason GH; Greve AM; Torp-Pedersen C; Køber L; Wachtell K
Eur J Prev Cardiol; 2014 Mar; 21(3):330-8. PubMed ID: 23012689
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.
Patti G; Chello M; Candura D; Pasceri V; D'Ambrosio A; Covino E; Di Sciascio G
Circulation; 2006 Oct; 114(14):1455-61. PubMed ID: 17000910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
